Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46


The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.

Cerna T, Hrabeta J, Eckschlager T, Frei E, Schmeiser HH, Arlt VM, Stiborová M.

Int J Mol Sci. 2018 Jan 5;19(1). pii: E164. doi: 10.3390/ijms19010164.


Host histone acetylation unlocks HDAC inhibitor potential.

Terranova-Barberio M, Thomas S, Munster PN.

Oncotarget. 2017 Nov 13;8(63):106161-106162. doi: 10.18632/oncotarget.22422. eCollection 2017 Dec 5. No abstract available.


Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.

Terranova-Barberio M, Pecori B, Roca MS, Imbimbo S, Bruzzese F, Leone A, Muto P, Delrio P, Avallone A, Budillon A, Di Gennaro E.

J Exp Clin Cancer Res. 2017 Dec 6;36(1):177. doi: 10.1186/s13046-017-0647-5.


Novel insights into chromosomal conformations in cancer.

Jia R, Chai P, Zhang H, Fan X.

Mol Cancer. 2017 Nov 17;16(1):173. doi: 10.1186/s12943-017-0741-5. Review.


A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.

Samaraweera L, Adomako A, Rodriguez-Gabin A, McDaid HM.

Sci Rep. 2017 May 15;7(1):1900. doi: 10.1038/s41598-017-01964-1.


Mammalian SWI/SNF Enzymes and the Epigenetics of Tumor Cell Metabolic Reprogramming.

Nickerson JA, Wu Q, Imbalzano AN.

Front Oncol. 2017 Apr 4;7:49. doi: 10.3389/fonc.2017.00049. eCollection 2017. Review.


Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.

Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN.

J Clin Oncol. 2017 Apr 10;35(11):1231-1239. doi: 10.1200/JCO.2016.70.5350. Epub 2017 Feb 21.


Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.

Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A.

BMC Cancer. 2016 Nov 25;16(1):918.


Advances in sarcoma diagnostics and treatment.

Dancsok AR, Asleh-Aburaya K, Nielsen TO.

Oncotarget. 2017 Jan 24;8(4):7068-7093. doi: 10.18632/oncotarget.12548. Review.


Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.

Beck A, Eberherr C, Hagemann M, Cairo S, Häberle B, Vokuhl C, von Schweinitz D, Kappler R.

Cancer Biol Ther. 2016 Nov;17(11):1168-1176. Epub 2016 Sep 16.


Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells.

Bhat J, Sosna J, Fritsch J, Quabius ES, Schütze S, Zeissig S, Ammerpohl O, Adam D, Kabelitz D.

Oncotarget. 2016 Oct 4;7(40):64743-64756. doi: 10.18632/oncotarget.11462.


A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.

Nilubol N, Merkel R, Yang L, Patel D, Reynolds JC, Sadowski SM, Neychev V, Kebebew E.

Clin Endocrinol (Oxf). 2017 Jan;86(1):128-133. doi: 10.1111/cen.13154. Epub 2016 Sep 8.


A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.

Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN.

Ann Oncol. 2016 May;27(5):947-52. doi: 10.1093/annonc/mdw044. Epub 2016 Feb 21.


Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.

Ji MM, Wang L, Zhan Q, Xue W, Zhao Y, Zhao X, Xu PP, Shen Y, Liu H, Janin A, Cheng S, Zhao WL.

Autophagy. 2015;11(12):2160-71. doi: 10.1080/15548627.2015.1082024.


Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.

Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D'Angelo G, Franco R, Budillon A, Di Gennaro E.

Oncotarget. 2016 Feb 16;7(7):7715-31. doi: 10.18632/oncotarget.6802.


Epigenetic treatment of solid tumours: a review of clinical trials.

Nervi C, De Marinis E, Codacci-Pisanelli G.

Clin Epigenetics. 2015 Dec 10;7:127. doi: 10.1186/s13148-015-0157-2. eCollection 2015. Review.


Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: a population-based study.

Fairhurst C, Watt I, Martin F, Bland M, Brackenbury WJ.

Sci Rep. 2015 Nov 18;5:16758. doi: 10.1038/srep16758.


Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.

Damm JK, Gordon S, Ehinger M, Jerkeman M, Gullberg U, Hultquist A, Drott K.

Exp Hematol Oncol. 2015 Jan 26;4:4. doi: 10.1186/2162-3619-4-4. eCollection 2015.


Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A.

BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875.

Supplemental Content

Support Center